PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29717476-2 2019 Verified DDI simulations provided dose recommendations for olaparib coadministration with clinically relevant CYP3A4 modulators to eliminate potential risk to patient safety or olaparib efficacy. olaparib 59-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 110-116 29717476-3 2019 When olaparib is given with strong/moderate CYP3A inhibitors, the dose should be reduced to 100/150 mg b.i.d. olaparib 5-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 44-49 29717476-8 2019 Olaparib was shown to be a weak inhibitor of CYP3A (1.6-fold increase in exposure of a sensitive CYP3A probe) and to have no effect on P-glycoprotein or UGT1A1 substrates. olaparib 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 45-50 29717476-8 2019 Olaparib was shown to be a weak inhibitor of CYP3A (1.6-fold increase in exposure of a sensitive CYP3A probe) and to have no effect on P-glycoprotein or UGT1A1 substrates. olaparib 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 97-102 30730634-11 2017 Olaparib is metabolised in the liver, mainly by cytochrome P450 isoenzymes CYP3A4 and CYP3A5. olaparib 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 75-81 28657402-8 2018 In a further study, olaparib (2-200 muM) functioned as a time-dependent inhibitor of CYP3A4/5 (KI, 72.2 muM and Kinact, 0.0675 min-1). olaparib 20-28 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 85-91 28657402-9 2018 Assessment of the CYP induction potential of olaparib (0.061-44 muM) showed minor concentration-related increases in CYP1A2 and more marked increases in CYP2B6 and CYP3A4 mRNA, compared with positive control activity; however, no significant change in CYP3A4/5 enzyme activity was observed. olaparib 45-53 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 164-170 28657402-9 2018 Assessment of the CYP induction potential of olaparib (0.061-44 muM) showed minor concentration-related increases in CYP1A2 and more marked increases in CYP2B6 and CYP3A4 mRNA, compared with positive control activity; however, no significant change in CYP3A4/5 enzyme activity was observed. olaparib 45-53 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 252-258 27745744-1 2016 PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA-mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). olaparib 27-35 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 227-233 27745744-2 2016 We assessed the potential of a CYP3A4 inhibitor (itraconazole) and inducer (rifampin) to alter the pharmacokinetic (PK) profile of olaparib following single oral tablet doses. olaparib 131-139 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 31-37 27745744-13 2016 IMPLICATIONS: Exposure to olaparib was significantly increased when co-administered with the potent CYP3A4 inhibitor itraconazole, and significantly decreased when co-administered with the potent CYP3A4 inducer rifampin, compared with olaparib alone. olaparib 26-34 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 100-106 27745744-13 2016 IMPLICATIONS: Exposure to olaparib was significantly increased when co-administered with the potent CYP3A4 inhibitor itraconazole, and significantly decreased when co-administered with the potent CYP3A4 inducer rifampin, compared with olaparib alone. olaparib 26-34 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 196-202 27745744-14 2016 Potent CYP3A4 enzyme inhibitors and inducers should be avoided during olaparib treatment. olaparib 70-78 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 7-13